JP2016511258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511258A5 JP2016511258A5 JP2015560325A JP2015560325A JP2016511258A5 JP 2016511258 A5 JP2016511258 A5 JP 2016511258A5 JP 2015560325 A JP2015560325 A JP 2015560325A JP 2015560325 A JP2015560325 A JP 2015560325A JP 2016511258 A5 JP2016511258 A5 JP 2016511258A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- independently
- oxazin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 CH 2 OH Chemical group 0.000 claims 109
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 150000001875 compounds Chemical class 0.000 claims 42
- 229910052731 fluorine Inorganic materials 0.000 claims 37
- 229910052799 carbon Inorganic materials 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 125000003342 alkenyl group Chemical group 0.000 claims 29
- 125000004432 carbon atom Chemical group C* 0.000 claims 28
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 27
- 125000005842 heteroatom Chemical group 0.000 claims 27
- 229910052760 oxygen Inorganic materials 0.000 claims 24
- 229910052801 chlorine Inorganic materials 0.000 claims 23
- 125000005309 thioalkoxy group Chemical group 0.000 claims 21
- 125000001153 fluoro group Chemical group F* 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000004663 dialkyl amino group Chemical group 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 14
- 125000002757 morpholinyl group Chemical group 0.000 claims 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 12
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 11
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- QMYGFTJCQFEDST-UHFFFAOYSA-N 3-methoxybutyl acetate Chemical group COC(C)CCOC(C)=O QMYGFTJCQFEDST-UHFFFAOYSA-N 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 7
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229940125810 compound 20 Drugs 0.000 claims 2
- 229940126086 compound 21 Drugs 0.000 claims 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- IDHAZTOESFWNSY-WMLDXEAASA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(Cl)=CC=2)=CC=C1F IDHAZTOESFWNSY-WMLDXEAASA-N 0.000 claims 2
- LUIXXFPAAMIKOX-LRDDRELGSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-chloropyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(Cl)=CC=2)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 LUIXXFPAAMIKOX-LRDDRELGSA-N 0.000 claims 2
- GZQHKBFOERBNAG-GUYCJALGSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 GZQHKBFOERBNAG-GUYCJALGSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- PCNDBEIQPLJGIC-KUHUBIRLSA-N (4r,6r)-4-[2-fluoro-5-[(2-methoxypyrido[3,4-b]pyrazin-5-yl)amino]phenyl]-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-2-amine Chemical compound N=1C=CC2=NC(OC)=CN=C2C=1NC(C=1)=CC=C(F)C=1[C@@]1(CF)C[C@H](C(F)(F)F)OC(N)=N1 PCNDBEIQPLJGIC-KUHUBIRLSA-N 0.000 claims 1
- CCHOGVQCNCTVED-HNAYVOBHSA-N (4s,6s)-4-[5-[(3-chloro-1,7-naphthyridin-8-yl)amino]-2-fluorophenyl]-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-2-amine Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC=2C3=NC=C(Cl)C=C3C=CN=2)=CC=C1F CCHOGVQCNCTVED-HNAYVOBHSA-N 0.000 claims 1
- GDGGLXWHVCHUOD-SJCJKPOMSA-N (4s,6s)-4-[5-[(7-chloropyrido[3,2-d]pyrimidin-4-yl)amino]-2-fluoropyridin-3-yl]-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-2-amine Chemical compound C=1C(NC=2C3=NC=C(Cl)C=C3N=CN=2)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 GDGGLXWHVCHUOD-SJCJKPOMSA-N 0.000 claims 1
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N 2,3-dimethylpyridine Chemical compound CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 claims 1
- KJBKHJJJGKNGTR-UGSOOPFHSA-N 4-[[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]amino]pyrido[3,2-d]pyrimidine-7-carbonitrile Chemical compound C=1C(NC=2C3=NC=C(C=C3N=CN=2)C#N)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 KJBKHJJJGKNGTR-UGSOOPFHSA-N 0.000 claims 1
- QJQLEDGUNULCGG-OXJNMPFZSA-N 8-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluoroanilino]-1,7-naphthyridine-3-carbonitrile Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC=2C3=NC=C(C=C3C=CN=2)C#N)=CC=C1F QJQLEDGUNULCGG-OXJNMPFZSA-N 0.000 claims 1
- LWXHQLQQXIEDPY-OXJNMPFZSA-N 8-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluoroanilino]-5-fluoro-1,7-naphthyridine-3-carbonitrile Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC=2C3=NC=C(C=C3C(F)=CN=2)C#N)=CC=C1F LWXHQLQQXIEDPY-OXJNMPFZSA-N 0.000 claims 1
- VFSFJNSLXGLHOI-LIRRHRJNSA-N 8-[[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]amino]-1,7-naphthyridine-3-carbonitrile Chemical compound C=1C(NC=2C3=NC=C(C=C3C=CN=2)C#N)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 VFSFJNSLXGLHOI-LIRRHRJNSA-N 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- BLNHQDSKCVQIOQ-GUYCJALGSA-N n-[3-[(4r,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 BLNHQDSKCVQIOQ-GUYCJALGSA-N 0.000 claims 1
- SXGOGHFRCNZQNM-SUMWQHHRSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C1F SXGOGHFRCNZQNM-SUMWQHHRSA-N 0.000 claims 1
- MOMLEQNWBDCETG-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3-chloro-5-cyanopyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2C(=CC(=CN=2)C#N)Cl)=CC=C1F MOMLEQNWBDCETG-KBXCAEBGSA-N 0.000 claims 1
- DDSHXFILKTVOHT-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3-chloro-5-methoxypyridine-2-carboxamide Chemical compound ClC1=CC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 DDSHXFILKTVOHT-KBXCAEBGSA-N 0.000 claims 1
- VBRNPACCSYLXRZ-MGPUTAFESA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-3-methylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound N1=C2C=CC=CN2C(C)=C1C(=O)NC(C=1)=CC=C(F)C=1[C@]1(CF)C[C@@H](C(F)(F)F)OC(N)=N1 VBRNPACCSYLXRZ-MGPUTAFESA-N 0.000 claims 1
- GXYRXKLMYVNONT-MAUKXSAKSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-(2,2,2-trifluoroethoxy)pyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(OCC(F)(F)F)=CC=2)=CC=C1F GXYRXKLMYVNONT-MAUKXSAKSA-N 0.000 claims 1
- BWKHCKWUYYLDFL-SUMWQHHRSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-bromo-3-chloropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2C(=CC(Br)=CN=2)Cl)=CC=C1F BWKHCKWUYYLDFL-SUMWQHHRSA-N 0.000 claims 1
- QKABRHMRLFQOCY-WMLDXEAASA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(Br)=CC=2)=CC=C1F QKABRHMRLFQOCY-WMLDXEAASA-N 0.000 claims 1
- OJXHVKRDKPVNQU-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloro-3-methoxypyridine-2-carboxamide Chemical compound COC1=CC(Cl)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 OJXHVKRDKPVNQU-KBXCAEBGSA-N 0.000 claims 1
- GSHVOYWQLKOCLX-KBXCAEBGSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Cl)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 GSHVOYWQLKOCLX-KBXCAEBGSA-N 0.000 claims 1
- CBFVEIDAVVTRFQ-HNAYVOBHSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyano-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(C#N)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 CBFVEIDAVVTRFQ-HNAYVOBHSA-N 0.000 claims 1
- QCMXWFUAVCHHIA-MAUKXSAKSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C1F QCMXWFUAVCHHIA-MAUKXSAKSA-N 0.000 claims 1
- NJIHNSPWTBSFKB-WMLDXEAASA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide Chemical compound C1[C@@H](C(F)(F)F)OC(N)=N[C@]1(CF)C1=CC(NC(=O)C=2N=CC(F)=CC=2)=CC=C1F NJIHNSPWTBSFKB-WMLDXEAASA-N 0.000 claims 1
- FOWQPYBFNSIGLL-SCLBCKFNSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxy-3-methylpyrazine-2-carboxamide Chemical compound CC1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 FOWQPYBFNSIGLL-SCLBCKFNSA-N 0.000 claims 1
- BLNHQDSKCVQIOQ-SUMWQHHRSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 BLNHQDSKCVQIOQ-SUMWQHHRSA-N 0.000 claims 1
- HHBMLXDPSJOPLK-MAUKXSAKSA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyridine-2-carboxamide Chemical compound N1=CC(OC)=CC=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 HHBMLXDPSJOPLK-MAUKXSAKSA-N 0.000 claims 1
- HCDBRYXKOZVMHM-MGPUTAFESA-N n-[3-[(4s,6s)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-6-chloro-3-methylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound N1=C2C=CC(Cl)=CN2C(C)=C1C(=O)NC(C=1)=CC=C(F)C=1[C@]1(CF)C[C@@H](C(F)(F)F)OC(N)=N1 HCDBRYXKOZVMHM-MGPUTAFESA-N 0.000 claims 1
- FLOQLFHUIOTUTO-KSSFIOAISA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Cl)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 FLOQLFHUIOTUTO-KSSFIOAISA-N 0.000 claims 1
- GLPZXCBSTJTISQ-YOEHRIQHSA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(Cl)=CC=2)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 GLPZXCBSTJTISQ-YOEHRIQHSA-N 0.000 claims 1
- MELQHVBGGSKVJQ-YJBOKZPZSA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 MELQHVBGGSKVJQ-YJBOKZPZSA-N 0.000 claims 1
- XQAPROTXNTWGLK-GUYCJALGSA-N n-[3-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 XQAPROTXNTWGLK-GUYCJALGSA-N 0.000 claims 1
- WTQJLKGKDKGXBB-ZBEGNZNMSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-3,5-dichloropyridine-2-carboxamide Chemical compound C=1C(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CN=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 WTQJLKGKDKGXBB-ZBEGNZNMSA-N 0.000 claims 1
- QDBLNVMBHVAXAF-SJCJKPOMSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-3-chloro-5-methoxypyridine-2-carboxamide Chemical compound ClC1=CC(OC)=CN=C1C(=O)NC1=CN=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 QDBLNVMBHVAXAF-SJCJKPOMSA-N 0.000 claims 1
- OYOWKRLQEBXXFF-SJCJKPOMSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-chloro-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Cl)=CN=C1C(=O)NC1=CN=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 OYOWKRLQEBXXFF-SJCJKPOMSA-N 0.000 claims 1
- AOLLQRLVRFPHMU-UGSOOPFHSA-N n-[5-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-6-fluoropyridin-3-yl]-5-cyano-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(C#N)=CN=C1C(=O)NC1=CN=C(F)C([C@@]2(C)N=C(N)O[C@@H](C2)C(F)(F)F)=C1 AOLLQRLVRFPHMU-UGSOOPFHSA-N 0.000 claims 1
- RPUXRRILZNMEFF-QFYYESIMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-3,5-dichloropyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2C(=CC(Cl)=CN=2)Cl)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 RPUXRRILZNMEFF-QFYYESIMSA-N 0.000 claims 1
- XUSLPMBGYMTYIP-QFYYESIMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-3-chloro-5-(trifluoromethyl)pyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2C(=CC(=CN=2)C(F)(F)F)Cl)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 XUSLPMBGYMTYIP-QFYYESIMSA-N 0.000 claims 1
- SEDNJKRDPITJTN-GTNSWQLSSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-3-chloro-5-cyanopyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2C(=CC(=CN=2)C#N)Cl)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 SEDNJKRDPITJTN-GTNSWQLSSA-N 0.000 claims 1
- FWHRMLYVMNQBGS-ZBEGNZNMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-5-chloropyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2N=CC(Cl)=CC=2)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 FWHRMLYVMNQBGS-ZBEGNZNMSA-N 0.000 claims 1
- JDFWETJUGPKDKZ-SJCJKPOMSA-N n-[6-[(4s,6s)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-5-fluoropyridin-2-yl]-5-cyanopyridine-2-carboxamide Chemical compound N=1C(NC(=O)C=2N=CC(=CC=2)C#N)=CC=C(F)C=1[C@]1(C)C[C@@H](C(F)(F)F)OC(N)=N1 JDFWETJUGPKDKZ-SJCJKPOMSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960005206 pyrazinamide Drugs 0.000 claims 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims 1
- 0 C*C(C1(*)N=C(N)OC(C(F)(F)F)C1(*)*)=*C(*)=*[*-] Chemical compound C*C(C1(*)N=C(N)OC(C(F)(F)F)C1(*)*)=*C(*)=*[*-] 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771615P | 2013-03-01 | 2013-03-01 | |
| US61/771,615 | 2013-03-01 | ||
| US201361826431P | 2013-05-22 | 2013-05-22 | |
| US61/826,431 | 2013-05-22 | ||
| US201461928898P | 2014-01-17 | 2014-01-17 | |
| US61/928,898 | 2014-01-17 | ||
| PCT/US2014/019100 WO2014134341A1 (en) | 2013-03-01 | 2014-02-27 | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511258A JP2016511258A (ja) | 2016-04-14 |
| JP2016511258A5 true JP2016511258A5 (enExample) | 2017-03-30 |
| JP6389830B2 JP6389830B2 (ja) | 2018-09-12 |
Family
ID=50349866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560325A Active JP6389830B2 (ja) | 2013-03-01 | 2014-02-27 | ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9296734B2 (enExample) |
| EP (1) | EP2961749B1 (enExample) |
| JP (1) | JP6389830B2 (enExample) |
| AU (2) | AU2014223334C1 (enExample) |
| CA (1) | CA2902212C (enExample) |
| MX (1) | MX366855B (enExample) |
| TW (1) | TW201446758A (enExample) |
| UY (1) | UY35361A (enExample) |
| WO (1) | WO2014134341A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5490692B2 (ja) | 2008-06-13 | 2014-05-14 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| PE20151794A1 (es) | 2013-03-08 | 2015-12-03 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso |
| BR112015019412A8 (pt) * | 2013-04-11 | 2019-11-12 | Hoffmann La Roche | inibidores de bace1, seus usos, e composição farmacêutica |
| CR20160352A (es) | 2014-02-19 | 2016-10-20 | H Lundbeck As | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| MX2018001699A (es) | 2015-08-12 | 2018-05-07 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. |
| TW201726651A (zh) | 2015-09-23 | 2017-08-01 | 健生藥品公司 | ２，３，４，５－四氫吡啶－６－胺衍生物 |
| WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
| AU2016375540A1 (en) | 2015-12-25 | 2018-07-19 | Shionogi & Co., Ltd. | Process and intermediates for preparation of thiazine derivatives |
| JP6616525B2 (ja) * | 2016-03-01 | 2019-12-04 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂａｃｅ１阻害剤 |
| MX386618B (es) * | 2016-12-15 | 2025-03-19 | Amgen Inc | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso. |
| MY199348A (en) * | 2017-04-27 | 2023-10-24 | Basf Se | Process for preparing optically active 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds |
| CN112313238B (zh) | 2018-04-27 | 2025-01-17 | 盐野义制药株式会社 | 具有选择性bace1抑制活性的四氢吡喃并噁嗪衍生物 |
| TWI797167B (zh) * | 2018-09-28 | 2023-04-01 | 德商巴地斯顏料化工廠 | 用於製備光學活性嘧啶鎓化合物之方法 |
| TWI780230B (zh) * | 2018-09-28 | 2022-10-11 | 德商巴地斯顏料化工廠 | 用於製備含硫之嘧啶鎓化合物之方法 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| CN113979993B (zh) * | 2021-11-29 | 2023-10-13 | 云南萃精生物科技有限责任公司 | 一种不对称合成（s）-烟碱的方法 |
| CN114561435B (zh) * | 2022-04-27 | 2022-08-30 | 南京科力硕生物科技有限公司 | 利用磁性碳纳米管固定化酶催化制备4-氯-3-乙基-1-甲基吡唑-5-甲酸的方法 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| US5942400A (en) | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
| DK1115874T3 (da) | 1998-09-24 | 2009-04-20 | Pharmacia & Upjohn Co Llc | Alzheimer's sygdom-sekretase |
| US20040234976A1 (en) | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| EP2343069B1 (en) | 2003-12-15 | 2016-03-02 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
| EP2612854B1 (en) | 2005-10-25 | 2015-04-29 | Shionogi&Co., Ltd. | Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors |
| CA2683887A1 (en) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group having inhibitory activity against production of amyloid beta protein |
| JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| CA2695114A1 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| TWI423970B (zh) | 2008-01-18 | 2014-01-21 | 衛材Ｒ＆Ｄ企管股份有限公司 | 經稠合之胺基二氫噻衍生物 |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| JP5490692B2 (ja) | 2008-06-13 | 2014-05-14 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| KR20110048491A (ko) | 2008-07-28 | 2011-05-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스피로아미노디하이드로티아진 유도체들 |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EP2500344A4 (en) * | 2009-11-13 | 2013-05-01 | Shionogi & Co | AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION |
| US20120245154A1 (en) | 2009-12-09 | 2012-09-27 | Shionogi & Co., Ltd. | Substituted aminothiazine derivative |
| JP5554346B2 (ja) | 2009-12-09 | 2014-07-23 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| EP2511269A4 (en) | 2009-12-11 | 2013-04-24 | Shionogi & Co | FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP |
| UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| WO2012078994A1 (en) | 2010-12-09 | 2012-06-14 | Janssen Pharmaceutica Nv | Imidazo [1, 2-a] pyridine sulfonamides as trpm8 modulators |
| US20130281449A1 (en) | 2011-01-12 | 2013-10-24 | Novartis Ag | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders |
| CA2824220C (en) | 2011-01-13 | 2020-09-01 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
| JP2014505689A (ja) | 2011-01-13 | 2014-03-06 | ノバルティス アーゲー | 代謝障害の処置用ｂａｃｅ−２阻害剤 |
| US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| MX2013011947A (es) | 2011-04-13 | 2014-01-16 | Merck Sharp & Dohme | Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso. |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| US20140235626A1 (en) | 2011-04-26 | 2014-08-21 | Shionogi & Co., Ltd. | Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing them |
| US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| BR112013031510A2 (pt) | 2011-06-07 | 2016-12-27 | Hoffmann La Roche | [1,3]oxazinas |
| JP2014516063A (ja) * | 2011-06-07 | 2014-07-07 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としてのハロゲン−アルキル−１，３オキサジン |
| US8927535B2 (en) | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| CN103874496A (zh) | 2011-08-22 | 2014-06-18 | 默沙东公司 | 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途 |
| UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| US20130073953A1 (en) | 2011-09-21 | 2013-03-21 | Timothy Onyenobi | News headline screenshot viewing system |
| WO2013054291A1 (en) | 2011-10-13 | 2013-04-18 | Novartis Ag | Novel oxazine derivatives and their use in the treatment of disease |
| CA2853221A1 (en) | 2011-10-24 | 2013-05-02 | Tohru Yamashita | Bicyclic compound |
| CA2856892C (en) * | 2012-01-26 | 2020-05-12 | F. Hoffmann-La Roche Ag | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| EP2827857A4 (en) | 2012-03-20 | 2016-03-30 | Elan Pharm Inc | SPIROCYCLIC DIHYDRO-THIAZINE AND INHIBITORS OF BACE DIHYDRO-OXAZINE AND COMPOSITIONS AND USES THEREOF |
| ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
| WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
| SG11201407576YA (en) | 2012-06-26 | 2015-03-30 | Hoffmann La Roche | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| HUE031764T2 (en) | 2012-10-26 | 2017-07-28 | Lilly Co Eli | Tetrahydropyrrolothiazine derivatives as BACE inhibitors |
| WO2014093190A1 (en) | 2012-12-14 | 2014-06-19 | Merck Sharp & Dohme Corp. | Bace inhibitors of iminothiadiazine dioxides |
| US9475784B2 (en) | 2012-12-19 | 2016-10-25 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| CA2894919A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5,c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2934534B1 (en) | 2012-12-21 | 2017-12-13 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
| MX2015008957A (es) * | 2013-01-22 | 2015-09-29 | Siena Biotech Spa | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| PE20151794A1 (es) | 2013-03-08 | 2015-12-03 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso |
| BR112015019412A8 (pt) * | 2013-04-11 | 2019-11-12 | Hoffmann La Roche | inibidores de bace1, seus usos, e composição farmacêutica |
| HK1213562A1 (zh) | 2013-04-26 | 2016-07-08 | 豪夫迈‧罗氏有限公司 | Bace抑制剂的合成 |
-
2014
- 2014-02-27 AU AU2014223334A patent/AU2014223334C1/en active Active
- 2014-02-27 JP JP2015560325A patent/JP6389830B2/ja active Active
- 2014-02-27 CA CA2902212A patent/CA2902212C/en active Active
- 2014-02-27 TW TW103106910A patent/TW201446758A/zh unknown
- 2014-02-27 EP EP14712418.4A patent/EP2961749B1/en active Active
- 2014-02-27 MX MX2015011313A patent/MX366855B/es active IP Right Grant
- 2014-02-27 WO PCT/US2014/019100 patent/WO2014134341A1/en not_active Ceased
- 2014-02-27 US US14/192,710 patent/US9296734B2/en active Active
- 2014-03-05 UY UY0001035361A patent/UY35361A/es not_active Application Discontinuation
-
2018
- 2018-06-25 AU AU2018204589A patent/AU2018204589A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511258A5 (enExample) | ||
| JP7556010B2 (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| JP2016510758A5 (enExample) | ||
| KR102485100B1 (ko) | 치환된 우레아 유도체 및 이의 약제학적 용도 | |
| CA2876690C (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| CN105294683B (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| JP2017523223A5 (enExample) | ||
| US20190345138A1 (en) | Heterocyclic amides as kinase inhibitors | |
| CA3085937A1 (en) | Diazaindole compounds | |
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| JP2012527483A (ja) | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 | |
| JP2016525135A (ja) | ＢＥＴタンパク質およびポロ様キナーゼの二重阻害薬としての置換されたジヒドロピリド［３，４−ｂ］ピラジノン類 | |
| CA2682665A1 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
| CA2957544C (en) | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| JP2017537110A (ja) | ヘテロ環式誘導体およびその使用 | |
| JP2010523522A5 (enExample) | ||
| WO2019224773A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
| JP2016503785A5 (enExample) | ||
| WO2020012357A1 (en) | Heterocyclic compounds and methods of use | |
| JP7628089B2 (ja) | 三環式化合物およびそれらの用途 | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| JP2020526549A5 (enExample) | ||
| JP2016540803A5 (enExample) | ||
| JP2017513887A5 (enExample) |